Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial ( NCT03938792 ) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects.
- Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial ( NCT03938792 ) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects.
- “These results support the potential for marstacimab to become the first once-weekly non-factor treatment for people with hemophilia B and a treatment option that helps address the diverse needs of patients with hemophilia A or B without inhibitors.
- The safety profile for marstacimab was consistent with Phase 1/2 results and treatment was generally well-tolerated.
- Pfizer currently has three Phase 3 programs investigating novel treatment options for people living with hemophilia.